|
US7709454B2
(en)
*
|
1997-06-20 |
2010-05-04 |
New York University |
Methods and compositions for inhibiting tumorigenesis
|
|
US7741298B2
(en)
*
|
1997-06-20 |
2010-06-22 |
New York University |
Method and compositions for inhibiting tumorigenesis
|
|
US6545004B1
(en)
|
1999-10-27 |
2003-04-08 |
Cytokinetics, Inc. |
Methods and compositions utilizing quinazolinones
|
|
US7230000B1
(en)
|
1999-10-27 |
2007-06-12 |
Cytokinetics, Incorporated |
Methods and compositions utilizing quinazolinones
|
|
US7671200B2
(en)
|
1999-10-27 |
2010-03-02 |
Cytokinetics, Inc. |
Quinazolinone KSP inhibitors
|
|
US7009049B2
(en)
|
2002-02-15 |
2006-03-07 |
Cytokinetics, Inc. |
Syntheses of quinazolinones
|
|
US7214800B2
(en)
|
2002-05-09 |
2007-05-08 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
|
US7166595B2
(en)
|
2002-05-09 |
2007-01-23 |
Cytokinetics, Inc. |
Compounds, methods and compositions
|
|
US7038048B2
(en)
|
2002-05-23 |
2006-05-02 |
Cytokinetics, Inc. |
3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
|
|
US7041676B2
(en)
|
2002-06-14 |
2006-05-09 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
|
JP2006501201A
(en)
|
2002-07-23 |
2006-01-12 |
サイトキネティクス・インコーポレーテッド |
Compounds, compositions and methods
|
|
EP1558083A4
(en)
|
2002-09-30 |
2008-04-16 |
Cytokinetics Inc |
Compounds, compositions, and methods
|
|
EP1692112A4
(en)
|
2003-12-08 |
2008-09-24 |
Cytokinetics Inc |
Compounds, compositions, and methods
|
|
EP1730280B1
(en)
*
|
2004-03-26 |
2018-10-24 |
Curis, Inc. |
Rna interference modulators of hedgehog signaling and uses thereof
|
|
US20090047282A1
(en)
*
|
2005-03-25 |
2009-02-19 |
Hideaki Tojo |
Prophylactic/Therapeutic Agent for Cancer
|
|
CN101336229B
(en)
|
2005-12-23 |
2012-06-13 |
西兰岛药物有限公司 |
Modified lysine-mimetic compounds
|
|
PL2468724T3
(en)
|
2006-12-21 |
2016-05-31 |
Zealand Pharma As |
Synthesis of pyrrolidine compounds
|
|
TWI433674B
(en)
|
2006-12-28 |
2014-04-11 |
Infinity Discovery Inc |
Cyclopamine analogs
|
|
EP3190121B1
(en)
|
2007-12-27 |
2019-02-20 |
Infinity Pharmaceuticals, Inc. |
Methods for stereoselective reduction of cyclopamine 4-en-3-one derivative
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
MX2010009372A
(en)
|
2008-02-26 |
2010-09-22 |
Takeda Pharmaceutical |
Fused heterocyclic derivative and use thereof.
|
|
WO2009126840A1
(en)
*
|
2008-04-11 |
2009-10-15 |
Galaxy Biotech, Llc |
Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
|
|
UA102250C2
(en)
|
2008-04-29 |
2013-06-25 |
Эли Лилли Энд Компани |
Disubstituted phthalazine hedgehog pathway antagonists
|
|
CN102202737B
(en)
|
2008-11-03 |
2014-03-26 |
伊莱利利公司 |
Disubstituted 2,3-phthalazine hedgehog pathway antagonists
|
|
EP2358698B1
(en)
|
2008-11-17 |
2012-09-05 |
Eli Lilly and Company |
Tetrasubstituted pyridazine as hedgehog pathway antagonists
|
|
KR101335770B1
(en)
|
2008-11-17 |
2013-12-12 |
일라이 릴리 앤드 캄파니 |
Tetrasubstituted pyridazine hedgehog pathway antagonist
|
|
AR077014A1
(en)
|
2009-06-19 |
2011-07-27 |
Lilly Co Eli |
COMPOUND DERIVED FROM FTALAZINE 1,4-DISPOSED, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER
|
|
WO2011017551A1
(en)
|
2009-08-05 |
2011-02-10 |
Infinity Pharmaceuticals, Inc. |
Enzymatic transamination of cyclopamine analogs
|
|
NZ598749A
(en)
|
2009-08-26 |
2013-01-25 |
Takeda Pharmaceutical |
Fused heterocyclic ring derivative and use thereof
|
|
WO2011024869A1
(en)
|
2009-08-26 |
2011-03-03 |
武田薬品工業株式会社 |
Fused heterocyclic ring derivative and use thereof
|
|
US8614208B2
(en)
|
2009-08-26 |
2013-12-24 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic ring derivative and use thereof
|
|
US8927718B2
(en)
|
2009-08-26 |
2015-01-06 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic ring derivative and use thereof
|
|
EP2571357B1
(en)
|
2010-05-21 |
2016-07-06 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
|
WO2012037217A1
(en)
|
2010-09-14 |
2012-03-22 |
Infinity Pharmaceuticals, Inc. |
Transfer hydrogenation of cyclopamine analogs
|
|
CN103298474B
(en)
|
2010-11-10 |
2016-06-29 |
无限药品股份有限公司 |
Heterocyclic compound and application thereof
|
|
TWI546305B
(en)
|
2011-01-10 |
2016-08-21 |
英菲尼提製藥股份有限公司 |
Method for preparing isoquinolinone and solid form of isoquinolinone
|
|
WO2013012918A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
AU2012284088B2
(en)
|
2011-07-19 |
2015-10-08 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
CA2846431A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CN105102000B
(en)
|
2012-11-01 |
2021-10-22 |
无限药品公司 |
Cancer therapy using PI3 kinase isoform modulators
|
|
AU2013352256A1
(en)
|
2012-11-29 |
2015-06-18 |
Strasspharma, Llc |
Methods of modulating follicle stimulating hormone activity
|
|
AU2014233520B2
(en)
|
2013-03-15 |
2019-02-21 |
The Regents Of The University Of California |
Modulators of the eIF2alpha pathway
|
|
EP2970194A1
(en)
|
2013-03-15 |
2016-01-20 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
US9192609B2
(en)
|
2013-04-17 |
2015-11-24 |
Hedgepath Pharmaceuticals, Inc. |
Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
|
|
SG10201709926VA
(en)
|
2013-05-30 |
2017-12-28 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
|
MX389256B
(en)
|
2013-10-04 |
2025-03-20 |
Infinity Pharmaceuticals Inc |
HETEROCYCLIC COMPOUNDS AND THEIR USES.
|
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CN104906113A
(en)
*
|
2014-03-12 |
2015-09-16 |
淄博赛维医药技术有限公司 |
Antitumor medicine
|
|
EA201691872A1
(en)
|
2014-03-19 |
2017-04-28 |
Инфинити Фармасьютикалз, Инк. |
HETEROCYCLIC COMPOUNDS FOR APPLICATION IN THE TREATMENT OF PI3K-GAMMA-MEDIATED DISORDERS
|
|
US20150320754A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
BR112017026103B1
(en)
|
2015-06-04 |
2023-10-03 |
Sol-Gel Technologies Ltd |
TOPICAL COMPOSITIONS WITH HEDGEHOG INHIBITOR COMPOUND, TOPICAL DELIVERY SYSTEM AND THEIR USES
|
|
CN108349985A
(en)
|
2015-09-14 |
2018-07-31 |
无限药品股份有限公司 |
Solid forms of isoquinolinones, processes for their preparation, compositions containing them and methods of their use
|
|
WO2017139497A1
(en)
|
2016-02-11 |
2017-08-17 |
PellePharm, Inc. |
Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
|
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3474856B1
(en)
|
2016-06-24 |
2022-09-14 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2018202865A1
(en)
|
2017-05-05 |
2018-11-08 |
Zealand Pharma A/S |
Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
|
|
CN116349204A
(en)
|
2020-10-13 |
2023-06-27 |
奋进生物医药公司 |
Methods of treating fibrosis
|
|
US12447148B2
(en)
|
2024-03-05 |
2025-10-21 |
Endeavor Biomedicines, Inc. |
Methods of improving lung function
|